Tumour microenvironment (TME) refers to the non-cancerous cells and proteins present in the tumour that support the growth of cancerous cells. It is a key factor which contributes to the development of both primary and secondary tumours. Understanding how TME interacts with tumour and identifying changes in the TME during early stages of cancer can provide new important information for diagnosis, treatment, and preventing metastasis. In addition, modulating TME in favour of host resistance can maximize the efficacy of existing anti-cancer immunotherapies.
There is growing evidence that tumors are sustained and promoted by uncontrolled inflammatory cytokines from the TME. Anogen has developed a series of mAbs with high specificity and affinity against pro-inflammatory cytokines including but not limited to TNF-α, MCP-1 (CCL2), GM-CSF, IL-2, IL-8 (CXCL8), IFN-, MCP-3, IL-1, MIP-1α IL-10, IL-15, IL-17A, IL-18, and TGF-β. These mAbs are being studied for potential diagnostic and therapeutic applications in regulating TME to reduce metastasis.